DOCSLIB.ORG

Preferred Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preferred Drug List October 2021 Preferred Drug List The Preferred Drug List, administered by CVS Caremark® on behalf of Siemens, is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • This drug list represents a summary of prescription coverage. It is this document. Products recently approved by the U.S. Food and not all-inclusive and does not guarantee coverage. The member’s Drug Administration (FDA) may not be covered upon release specific prescription benefit plan design may not cover certain to the market. products or categories, regardless of their appearance in this • You may be responsible for the full cost of non-formulary products document. Products recently approved by the FDA may not be that are not covered without a prior authorization for medical covered upon release to the market. necessity. • The member's prescription benefit plan may have a different • For specific information regarding your prescription benefit copay for specific products on the list. coverage and copay1 information, please visit Caremark.com • Unless specifically indicated, drug list products will include all or contact a CVS Caremark Customer Care representative dosage forms. at 1-866-478-5802. • In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. ANALGESICS fentanyl transdermal SUPRAX itraconazole fentanyl transmucosal terbinafine tablet ANTINEOPLASTIC § ERYTHROMYCINS / § COX-2 INHIBITORS lozenge AGENTS MACROLIDES ANTIVIRALS celecoxib hydrocodone ext-rel HORMONAL hydrocodone-acetaminophen azithromycin § CYTOMEGALOVIRUS § GOUT ANTINEOPLASTIC AGENTS hydromorphone clarithromycin AGENTS § ANTIANDROGENS allopurinol hydromorphone ext-rel clarithromycin ext-rel valganciclovir colchicine tablet methadone erythromycins bicalutamide probenecid morphine DIFICID § HERPES AGENTS CARDIOVASCULAR MITIGARE morphine ext-rel acyclovir capsule, tablet § FLUOROQUINOLONES morphine suppository valacyclovir § ACE INHIBITORS § NSAIDs oxycodone ciprofloxacin diclofenac sodium § INFLUENZA AGENTS fosinopril oxycodone-acetaminophen levofloxacin ibuprofen lisinopril tramadol (except NDC^ 52817019610) moxifloxacin oseltamivir meloxicam tablet quinapril tramadol ext-rel tablet RELENZA naproxen (except naproxen CR or § PENICILLINS ramipril BELBUCA naproxen suspension) amoxicillin § MISCELLANEOUS NUCYNTA § ACE INHIBITOR / amoxicillin-clavulanate clindamycin § NSAIDs, COMBINATIONS NUCYNTA ER DIURETIC COMBINATIONS dicloxacillin ivermectin SUBSYS fosinopril-hydrochlorothiazide diclofenac sodium- penicillin VK linezolid XTAMPZA ER lisinopril-hydrochlorothiazide misoprostol metronidazole § TETRACYCLINES quinapril-hydrochlorothiazide ANTI-INFECTIVES nitrofurantoin (except NDC^ § NSAIDs, TOPICAL doxycycline hyclate 20 mg 70408023932) § ANGIOTENSIN II diclofenac sodium gel 1% ANTIBACTERIALS doxycycline hyclate capsule pyrimethamine RECEPTOR ANTAGONISTS / diclofenac sodium solution § CEPHALOSPORINS minocycline sulfamethoxazole- DIURETIC COMBINATIONS tetracycline cefdinir trimethoprim § OPIOID ANALGESICS candesartan / candesartan- cefprozil vancomycin capsule buprenorphine transdermal § ANTIFUNGALS hydrochlorothiazide cefuroxime axetil EMVERM codeine-acetaminophen fluconazole irbesartan / irbesartan- cephalexin XIFAXAN 550 MG Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit Caremark.com or contact a CVS Caremark Customer Care representative. hydrochlorothiazide lorazepam § MISCELLANEOUS MIGRAINE § BETA-BLOCKERS losartan / losartan- oxazepam AGENTS ACUTE MIGRAINE AGENTS atenolol hydrochlorothiazide bupropion § Triptans carvedilol § ANTICONVULSANTS olmesartan / olmesartan- bupropion ext-rel (except carvedilol phosphate ext-rel carbamazepine eletriptan hydrochlorothiazide bupropion ext-rel tablet 450 mg) metoprolol succinate ext-rel carbamazepine ext-rel naratriptan telmisartan / telmisartan- mirtazapine metoprolol tartrate clobazam rizatriptan hydrochlorothiazide trazodone sumatriptan valsartan / valsartan- nadolol diazepam rectal gel zolmitriptan hydrochlorothiazide pindolol divalproex sodium § ANTIPARKINSONIAN propranolol divalproex sodium ext-rel AGENTS ONZETRA XSAIL § ANGIOTENSIN II ZEMBRACE SYMTOUCH propranolol ext-rel ethosuximide amantadine RECEPTOR ANTAGONIST / ZOMIG NASAL SPRAY BYSTOLIC gabapentin carbidopa-levodopa CALCIUM CHANNEL lamotrigine carbidopa-levodopa ext-rel § CALCIUM CHANNEL Miscellaneous BLOCKER COMBINATIONS lamotrigine ext-rel carbidopa-levodopa- BLOCKERS NURTEC ODT amlodipine-olmesartan levetiracetam entacapone amlodipine REYVOW amlodipine-telmisartan levetiracetam ext-rel entacapone UBRELVY diltiazem ext-rel (except generics amlodipine-valsartan oxcarbazepine pramipexole for CARDIZEM LA) phenobarbital pramipexole ext-rel PREVENTIVE MIGRAINE § ANGIOTENSIN II nifedipine ext-rel phenytoin rasagiline AGENTS RECEPTOR ANTAGONIST / verapamil ext-rel phenytoin sodium extended ropinirole CALCIUM CHANNEL Monoclonal Antibodies primidone ropinirole ext-rel BLOCKER / DIURETIC § CALCIUM CHANNEL AIMOVIG rufinamide selegiline COMBINATIONS BLOCKER / ANTILIPEMIC AJOVY tiagabine NEUPRO COMBINATIONS EMGALITY amlodipine-valsartan- topiramate hydrochlorothiazide amlodipine-atorvastatin valproic acid ANTIPSYCHOTICS § MUSCULOSKELETAL olmesartan-amlodipine- § DIGITALIS GLYCOSIDES zonisamide § ATYPICALS THERAPY AGENTS hydrochlorothiazide FYCOMPA aripiprazole digoxin cyclobenzaprine (except NAYZILAM § ANTIARRHYTHMICS clozapine cyclobenzaprine tablet 7.5 mg) § DIRECT RENIN OXTELLAR XR olanzapine disopyramide INHIBITORS / DIURETIC TROKENDI XR quetiapine § NARCOLEPSY sotalol VALTOCO COMBINATIONS quetiapine ext-rel armodafinil MULTAQ VIMPAT aliskiren risperidone modafinil XCOPRI ziprasidone SUNOSI ANTILIPEMICS TEKTURNA HCT ACL INHIBITORS / § ANTIDEMENTIA ABILIFY MAINTENA § DIURETICS LATUDA POSTHERPETIC COMBINATIONS donepezil amiloride PERSERIS NEURALGIA (PHN) NEXLETOL galantamine furosemide VRAYLAR GRALISE NEXLIZET galantamine ext-rel hydrochlorothiazide memantine § ATTENTION DEFICIT PSYCHOTHERAPEUTIC - § BILE ACID RESINS metolazone rivastigmine spironolactone- HYPERACTIVITY DISORDER MISCELLANEOUS cholestyramine rivastigmine transdermal hydrochlorothiazide amphetamine- § OPIOID ANTAGONISTS colesevelam NAMZARIC dextroamphetamine mixed torsemide naloxone injection § CHOLESTEROL triamterene ANTIDEPRESSANTS salts NARCAN NASAL SPRAY ABSORPTION INHIBITORS triamterene- amphetamine- § SELECTIVE SEROTONIN dextroamphetamine mixed § PARTIAL OPIOID AGONIST ezetimibe hydrochlorothiazide REUPTAKE INHIBITORS salts ext-rel † / OPIOID ANTAGONIST (SSRIs) § FIBRATES HEART FAILURE atomoxetine COMBINATIONS citalopram fenofibrate (except fenofibrate capsule BIDIL dexmethylphenidate ext-rel buprenorphine-naloxone escitalopram 50 mg, 130 mg; fenofibrate tablet 40 mg, CORLANOR guanfacine ext-rel sublingual fluoxetine (except fluoxetine tablet 60 120 mg) ENTRESTO methylphenidate ZUBSOLV mg, fluoxetine tablet [generics for † fenofibric acid delayed-rel methylphenidate ext-rel § NITRATES SARAFEM]) MYDAYIS PSEUDOBULBAR AFFECT § HMG-CoA REDUCTASE isosorbide dinitrate (except paroxetine HCl VYVANSE AGENTS INHIBITORS / isosorbide dinitrate 40 mg) paroxetine HCl ext-rel (except NUEDEXTA COMBINATIONS isosorbide mononitrate NDC^ 60505367503) § FIBROMYALGIA ENDOCRINE AND atorvastatin nitroglycerin lingual spray sertraline pregabalin METABOLIC ezetimibe-simvastatin nitroglycerin sublingual TRINTELLIX HYPNOTICS fluvastatin § MISCELLANEOUS § SEROTONIN § NONBENZODIAZEPINES § ANDROGENS lovastatin ranolazine ext-rel NOREPINEPHRINE testosterone gel (except authorized pravastatin eszopiclone REUPTAKE INHIBITORS generics for TESTIM and VOGELXO) rosuvastatin ramelteon CENTRAL NERVOUS (SNRIs) testosterone solution simvastatin zolpidem ANDRODERM SYSTEM desvenlafaxine ext-rel zolpidem ext-rel NATESTO § NIACINS duloxetine ANTIANXIETY BELSOMRA venlafaxine niacin ext-rel ANTIDIABETICS § BENZODIAZEPINES venlafaxine ext-rel capsule § TRICYCLICS AMYLIN ANALOGS § OMEGA-3 FATTY ACIDS alprazolam doxepin omega-3 acid ethyl esters clonazepam
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • Azelaic Acid
    Azelaic Acid (FINACEA) Topical Foam 15% National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Azelaic acid is a naturally occurring C9-dicarboxylic acid that is found in plants Action (such as whole grain cereals), animals and humans. Azelaic acid has antiinflammatory, antioxidative and antikeratinizing effects. In rosacea skin, azelaic acid decreases cathelicidin levels and kallikrein 5 (KLK5) activity and possibly inhibits toll-like receptor 2 (TLR2) expression.1 A 15% gel formulation has been marketed for rosacea, and 20% cream has been available for acne vulgaris. The newer foam formulation consists of an oil- in-water emulsion and was designed to have a higher lipid content than the gel for dry and sensitive skin. Indication(s) Under Review Topical treatment of inflammatory papules and pustules of mild to moderate in This Document rosacea. Dosage Form(s) Under Foam, 15% Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category B Executive Summary Efficacy There have been no head-to-head trials comparing the foam and gel formulations of azelaic acid in terms of safety, tolerability and efficacy in the treatment of papulopustular (PP) rosacea.. In two major randomized clinical trials, azelaic acid foam produced small benefits over vehicle foam in achieving Investigator’s Global Assessment (IGA) treatment success (NNTs of 9.2 and 11.5) and in reducing inflammatory lesion counts.
    [Show full text]
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Use of Undiluted Tea-Tree Oil As a Cosmetic
    Federal Institute for Risk Assessment (BfR) Use of undiluted tea-tree oil as a cosmetic Opinion of the Federal Insitute for Risk Assessment (BfR), 1th September 2003 Background Recently there has been an increasing amount of reports on contact-allergic eczema in con- junction with the use of tea-tree oil. Tea-tree oil is sold as a pure natural product, highly con- centrated and undiluted in cosmetics. Tea-tree oil is advertised as a universal remedy al- though there is no marketing authorisation as a pharmaceutical product. Concentrated tea-tree oil has been classified as harmful according to the self-classification of the International Fragrance Association (IFRA) and is labelled with R-phrases R 22 (harmful if swallowed) R 38 (irritating to skin) and R 65 (may cause lung damage if swallowed) as well as the symbol Xn (harmful) (IFRA Labelling Manual 1, 2001). These indications of health hazards are also part of the safety data sheets of raw material suppliers. At the 65th and 66th meetings of the Cosmetics Committee at the Federal Institute for Risk Assessment (BfR), health risks associated with the use of undiluted and highly concentrated tea-tree oil in cosmetic products were discussed extensively. Result Tea-tree oil is a mixture of various terpenes extracted from the Australian tea-tree. Undiluted tea-tree oil is a pure natural product. In the presence of atmospheric oxygen but also when exposed to light and higher temperatures, oxidation processes occur leading to the formation of peroxides, epoxides and endoperoxides which have a sensitising potency and may trigger allergic skin reactions.
    [Show full text]
  • Drug Information Center Highlights of FDA Activities
    Drug Information Center Highlights of FDA Activities – 3/1/21 – 3/31/21 FDA Drug Safety Communications & Drug Information Updates: Ivermectin Should Not Be Used to Treat or Prevent COVID‐19: MedWatch Update 3/5/21 The FDA advised consumers against the use of ivermectin for the treatment or prevention of COVID‐19 following reports of patients requiring medical support and hospitalization after self‐medicating. Ivermectin has not been approved for this use and is not an anti‐viral drug. Health professionals are encouraged to report adverse events associated with ivermectin to MedWatch. COVID‐19 EUA FAERS Public Dashboard 3/15/21 The FDA launched an update to the FDA Adverse Event Reporting System (FAERS) Public Dashboard that provides weekly updates of adverse event reports submitted to FAERS for drugs and therapeutic biologics used under an Emergency Use Authorization (EUA) during the COVID‐19 public health emergency. Monoclonal Antibody Products for COVID‐19 – Fact Sheets Updated to Address Variants 3/18/21 The FDA authorized revised fact sheets for health care providers to include susceptibility of SARS‐CoV‐2 variants to each of the monoclonal antibody products available through EUA for the treatment of COVID‐19 (bamlanivimab, bamlanivimab and etesevimab, and casirivimab and imdevimab). Abuse and Misuse of the Nasal Decongestant Propylhexedrine Causes Serious Harm 3/25/21 The FDA warned that abuse and misuse of the nasal decongestant propylhexedrine, sold OTC in nasal decongestant inhalers, has been increasingly associated with cardiovascular and mental health problems. The FDA has recommended product design changes to support safe use, such as modifications to preclude tampering and limits on the content within the device.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • 2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
    2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]